{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T05:30:42Z","timestamp":1771997442103,"version":"3.50.1"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009337","name":"Saitama Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Opinion Statement<\/jats:title>\n                  <jats:p>Melanoma is one of the most aggressive and lethal forms of skin cancer, with acral melanoma (AM) associated with the poorer prognosis among melanoma subtypes. Historically, it was considered that more extensive surgery could prolong survival; however, multiple randomized trials have demonstrated that greater surgical intervention does not improve survival. Over the past few years, novel therapeutic agents including immune checkpoint inhibitors and molecular-targeted drugs have remarkably improved prognosis of melanoma and potentially reduced the role of surgery. Furthermore, predictive models that integrate clinicopathologic features and gene expression profiling may further optimize patient selection and guidance for surgical de-escalation. In parallel, the use of these agents in adjuvant and neoadjuvant settings highlights the need for multimodal approaches combined with surgery. However, the landmark clinical trials have included few cases of AM, which is rare melanoma subtype in Western populations. Because of its unique molecular alterations, the applicability of findings from Western-based clinical trials to AM remains uncertain, leading to a lack of high-level evidence for this subtype. In this article, we review the available, albeit limited, evidence on surgical management for AM and discuss future perspectives and challenges for optimizing treatment strategies for this distinct melanoma subtype.<\/jats:p>","DOI":"10.1007\/s11864-025-01361-1","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:22:10Z","timestamp":1761556930000},"page":"1086-1095","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Current Surgical Management for Acral Melanoma"],"prefix":"10.1007","volume":"26","author":[{"given":"Shigeru","family":"Koizumi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Inozume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"1361_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1046\/j.1365-2133.149.s64.8_65.x","volume":"149","author":"DJ Eedy","year":"2003","unstructured":"Eedy DJ. Surgical treatment of melanoma. Br J Dermatol. 2003;149:2\u201312.","journal-title":"Br J Dermatol"},{"key":"1361_CR2","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507\u201316.","journal-title":"N Engl J Med"},{"key":"1361_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122\u201333.","journal-title":"N Engl J Med"},{"key":"1361_CR4","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1158\/1078-0432.CCR-13-2054","volume":"20","author":"AM Menzies","year":"2014","unstructured":"Menzies AM, Long GV. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clin Cancer Res. 2014;20:2035\u201343.","journal-title":"Clin Cancer Res"},{"key":"1361_CR5","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521\u201332.","journal-title":"N Engl J Med"},{"key":"1361_CR6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"key":"1361_CR7","doi-asserted-by":"publisher","first-page":"114073","DOI":"10.1016\/j.ejca.2024.114073","volume":"204","author":"D Schadendorf","year":"2024","unstructured":"Schadendorf D, Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, et al. COLUMBUS 7-year update: A randomized, open-label, phase III trial of Encorafenib plus binimetinib versus Vemurafenib or Encorafenib in patients with BRAF V600E\/K-mutant melanoma. Eur J Cancer. 2024;204:114073.","journal-title":"Eur J Cancer"},{"key":"1361_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392:11\u201322.","journal-title":"N Engl J Med"},{"key":"1361_CR9","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1200\/JCO.22.01599","volume":"41","author":"C Robert","year":"2023","unstructured":"Robert C, Carlino MS, McNeil C, Ribas A, Grob JJ, Schachter J, et al. Seven-year follow-up of the phase III KEYNOTE-006 study: pembrolizumab versus ipilimumab in advanced melanoma. J Clin Oncol. 2023;41:3998\u20134003.","journal-title":"J Clin Oncol"},{"key":"1361_CR10","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/1346-8138.17086","volume":"51","author":"S Koizumi","year":"2024","unstructured":"Koizumi S, Inozume T, Nakamura Y. Current surgical management for melanoma. J Dermatol. 2024;51:312\u201323.","journal-title":"J Dermatol"},{"key":"1361_CR11","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1056\/NEJM198805053181804","volume":"318","author":"U Veronesi","year":"1988","unstructured":"Veronesi U, Cascinelli N, Adamus J, Balch C, Bandiera D, Barchuk A, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3\u00a0cm. N Engl J Med. 1988;318:1159\u201362.","journal-title":"N Engl J Med"},{"key":"1361_CR12","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/archsurg.1991.01410280036004","volume":"126","author":"U Veronesi","year":"1991","unstructured":"Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg. 1991;126:438\u201341.","journal-title":"Arch Surg"},{"key":"1361_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/1097-0142(19920115)69:2<421::AID-CNCR2820690224>3.0.CO;2-L","volume":"69","author":"PJ Heenan","year":"1992","unstructured":"Heenan PJ, English DR, Holman CD, Armstrong BK. The effects of surgical treatment on survival and local recurrence of cutaneous malignant melanoma. Cancer. 1992;69:421\u20136.","journal-title":"Cancer"},{"key":"1361_CR14","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/1097-0142(20001001)89:7<1495::AID-CNCR12>3.0.CO;2-D","volume":"89","author":"G Cohn-Cedermark","year":"2000","unstructured":"Cohn-Cedermark G, Rutqvist LE, Andersson R, Breivald M, Ingvar C, Johansson H, et al. Long term results of a randomized study by the Swedish melanoma study group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer. 2000;89:1495\u2013501.","journal-title":"Cancer"},{"key":"1361_CR15","first-page":"101","volume":"8","author":"CM Balch","year":"2001","unstructured":"Balch CM, Soong SJ, Smith T, Ross MI, Urist MM, Karakousis CP, et al. Long-term results of a prospective surgical trial comparing 2\u00a0cm vs. 4\u00a0cm excision margins for 740 patients with 1\u20134\u00a0mm melanomas. Ann Surg Oncol. 2001;8:101\u20138.","journal-title":"Ann Surg Oncol"},{"key":"1361_CR16","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/cncr.11272","volume":"97","author":"D Khayat","year":"2003","unstructured":"Khayat D, Rixe O, Martin G, Soubrane C, Banzet M, Bazex JA, et al. Surgical margins in cutaneous melanoma (2\u00a0cm versus 5\u00a0cm for lesions measuring less than 2.1-mm thick). Cancer. 2003;97:1941\u20136.","journal-title":"Cancer"},{"key":"1361_CR17","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJMoa030681","volume":"350","author":"JM Thomas","year":"2004","unstructured":"Thomas JM, Newton-Bishop J, A\u2019Hern R, Coombes G, Timmons M, Evans J, et al. Excision margins in high-risk malignant melanoma. N Engl J Med. 2004;350:757\u201366.","journal-title":"N Engl J Med"},{"key":"1361_CR18","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1056\/NEJMoa060992","volume":"355","author":"DL Morton","year":"2006","unstructured":"Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307\u201317.","journal-title":"N Engl J Med"},{"key":"1361_CR19","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(11)61546-8","volume":"378","author":"P Gillgren","year":"2011","unstructured":"Gillgren P, Drzewiecki KT, Niin M, Gullestad HP, Hellborg H, M\u00e5nsson-Brahme E, et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet. 2011;378:1635\u201342.","journal-title":"Lancet"},{"key":"1361_CR20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/01.sla.0000181092.50141.fa","volume":"242","author":"DL Morton","year":"2005","unstructured":"Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242:302\u201311. discussion 11\u2009\u2013\u20093.","journal-title":"Ann Surg"},{"key":"1361_CR21","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211\u201322.","journal-title":"N Engl J Med"},{"key":"1361_CR22","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","volume":"17","author":"U Leiter","year":"2016","unstructured":"Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:757\u201367.","journal-title":"Lancet Oncol"},{"key":"1361_CR23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1310460","volume":"370","author":"DL Morton","year":"2014","unstructured":"Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599\u2013609.","journal-title":"N Engl J Med"},{"key":"1361_CR24","doi-asserted-by":"publisher","first-page":"115376","DOI":"10.1016\/j.ejca.2025.115376","volume":"220","author":"ACJ van Akkooi","year":"2025","unstructured":"van Akkooi ACJ, Eggermont AMM. Reduction in surgical interventions in melanoma. Eur J Cancer. 2025;220:115376.","journal-title":"Eur J Cancer"},{"key":"1361_CR25","doi-asserted-by":"crossref","unstructured":"Fukushima S, Ito T, Asai J, Igaki H, Tanaka R, Namikawa K et al. Japanese dermatological association guidelines: clinical questions of guidelines for melanoma 2025. J Dermatol. 2025.","DOI":"10.1111\/1346-8138.17740"},{"key":"1361_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545:175\u201380.","journal-title":"Nature"},{"key":"1361_CR27","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/ced.13243","volume":"42","author":"A Desai","year":"2017","unstructured":"Desai A, Ugorji R, Khachemoune A. Acral melanoma foot lesions. Part 1: epidemiology, aetiology, and molecular pathology. Clin Exp Dermatol. 2017;42:845\u20138.","journal-title":"Clin Exp Dermatol"},{"key":"1361_CR28","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377:2500\u20131.","journal-title":"N Engl J Med"},{"key":"1361_CR29","doi-asserted-by":"crossref","unstructured":"Rossi AJ, Verbus EA, Faries MB, Moncrieff M, Henderson M, Hernandez JM et al. A phase III, Multicenter, randomized controlled trial investigating 1-cm versus 2-cm surgical excision margins for stage II primary cutaneous melanoma (MelMarT-II). Ann Surg Oncol. 2022.","DOI":"10.1245\/s10434-022-11766-z"},{"key":"1361_CR30","doi-asserted-by":"publisher","first-page":"31432","DOI":"10.1038\/srep31432","volume":"6","author":"J Lv","year":"2016","unstructured":"Lv J, Dai B, Kong Y, Shen X, Kong J. Acral melanoma in chinese: A clinicopathological and prognostic study of 142 cases. Sci Rep. 2016;6:31432.","journal-title":"Sci Rep"},{"key":"1361_CR31","doi-asserted-by":"publisher","first-page":"107692","DOI":"10.1016\/j.ypmed.2023.107692","volume":"175","author":"DM Holman","year":"2023","unstructured":"Holman DM, King JB, White A, Singh SD, Lichtenfeld JL. Acral lentiginous melanoma incidence by sex, race, ethnicity, and stage in the united States, 2010\u20132019. Prev Med. 2023;175:107692.","journal-title":"Prev Med"},{"key":"1361_CR32","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/cam4.2110","volume":"8","author":"Y Fujisawa","year":"2019","unstructured":"Fujisawa Y, Yoshikawa S, Minagawa A, Takenouchi T, Yokota K, Uchi H, et al. Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. Cancer Med. 2019;8:2146\u201356.","journal-title":"Cancer Med"},{"key":"1361_CR33","doi-asserted-by":"publisher","first-page":"100947","DOI":"10.1016\/j.neo.2023.100947","volume":"46","author":"LAD Carvalho","year":"2023","unstructured":"Carvalho LAD, Aguiar FC, Smalley KSM, Possik PA. Acral melanoma: new insights into the immune and genomic landscape. Neoplasia. 2023;46:100947.","journal-title":"Neoplasia"},{"key":"1361_CR34","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1056\/NEJMc1512354","volume":"374","author":"A Minagawa","year":"2016","unstructured":"Minagawa A, Omodaka T, Okuyama R. Melanomas and mechanical stress points on the plantar surface of the foot. N Engl J Med. 2016;374:2404\u20136.","journal-title":"N Engl J Med"},{"key":"1361_CR35","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1038\/s41467-022-29925-x","volume":"13","author":"J Seo","year":"2022","unstructured":"Seo J, Kim H, Min KI, Kim C, Kwon Y, Zheng Z, et al. Weight-bearing activity impairs nuclear membrane and genome integrity via YAP activation in plantar melanoma. Nat Commun. 2022;13:2214.","journal-title":"Nat Commun"},{"issue":"9","key":"1361_CR36","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.annonc.2020.05.031","volume":"31","author":"Y Nakamura","year":"2020","unstructured":"Nakamura Y, Namikawa K, Yoshino K, Yoshikawa S, Uchi H, Goto K, et al. Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients. Ann Oncol. 2020;31(9):1198\u2013206.","journal-title":"Ann Oncol"},{"key":"1361_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2022.02.026","volume":"167","author":"OJ van Not","year":"2022","unstructured":"van Not OJ, de Meza MM, van den Eertwegh AJM, Haanen JB, Blank CU, Aarts MJB, et al. Response to immune checkpoint inhibitors in acral melanoma: a nationwide cohort study. Eur J Cancer. 2022;167:70\u201380.","journal-title":"Eur J Cancer"},{"key":"1361_CR38","doi-asserted-by":"crossref","unstructured":"Bhave P, Ahmed T, Lo SN, Shoushtari A, Zaremba A, Versluis JM et al. Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma. J Immunother Cancer. 2022;10.","DOI":"10.1136\/jitc-2022-004668"},{"key":"1361_CR39","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/cam4.3781","volume":"10","author":"D Ogata","year":"2021","unstructured":"Ogata D, Haydu LE, Glitza IC, Patel SP, Tawbi HA, McQuade JL, et al. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. Cancer Med. 2021;10:2293\u20139.","journal-title":"Cancer Med"},{"key":"1361_CR40","doi-asserted-by":"publisher","first-page":"e70360","DOI":"10.1002\/cam4.70360","volume":"13","author":"T Hida","year":"2024","unstructured":"Hida T, Idogawa M, Kato J, Kiniwa Y, Horimoto K, Sato S, et al. Genetic characteristics of Cutaneous, Acral, and mucosal melanoma in Japan. Cancer Med. 2024;13:e70360.","journal-title":"Cancer Med"},{"key":"1361_CR41","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMoa050092","volume":"353","author":"JA Curtin","year":"2005","unstructured":"Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135\u201347.","journal-title":"N Engl J Med"},{"key":"1361_CR42","doi-asserted-by":"publisher","first-page":"7250","DOI":"10.1038\/s41467-022-34877-3","volume":"13","author":"C Zhang","year":"2022","unstructured":"Zhang C, Shen H, Yang T, Li T, Liu X, Wang J, et al. A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma. Nat Commun. 2022;13:7250.","journal-title":"Nat Commun"},{"key":"1361_CR43","doi-asserted-by":"publisher","first-page":"eadk8832","DOI":"10.1126\/scitranslmed.adk8832","volume":"16","author":"T Minowa","year":"2024","unstructured":"Minowa T, Murata K, Mizue Y, Murai A, Nakatsugawa M, Sasaki K, et al. Single-cell profiling of acral melanoma infiltrating lymphocytes reveals a suppressive tumor microenvironment. Sci Transl Med. 2024;16:eadk8832.","journal-title":"Sci Transl Med"},{"key":"1361_CR44","doi-asserted-by":"crossref","unstructured":"Dousset L, Poizeau F, Robert C, Mansard S, Mortier L, Caumont C et al. Positive association between location of Melanoma, ultraviolet Signature, tumor mutational Burden, and response to Anti-PD-1 therapy. JCO Precis Oncol. 2021;5.","DOI":"10.1200\/PO.21.00084"},{"key":"1361_CR45","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.annonc.2022.06.004","volume":"33","author":"F Dimitriou","year":"2022","unstructured":"Dimitriou F, Namikawa K, Reijers ILM, Buchbinder EI, Soon JA, Zaremba A, et al. Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Ann Oncol. 2022;33:968\u201380.","journal-title":"Ann Oncol"},{"key":"1361_CR46","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bjd.21241","volume":"187","author":"X Bai","year":"2022","unstructured":"Bai X, Shoushtari AN, Betof Warner A, Si L, Tang B, Cui C, et al. Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. Br J Dermatol. 2022;187:401\u201310.","journal-title":"Br J Dermatol"},{"key":"1361_CR47","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/(SICI)1098-2388(199806)14:4<272::AID-SSU2>3.0.CO;2-#","volume":"14","author":"N Cascinelli","year":"1998","unstructured":"Cascinelli N. Margin of resection in the management of primary melanoma. Semin Surg Oncol. 1998;14:272\u20135.","journal-title":"Semin Surg Oncol"},{"key":"1361_CR48","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S1470-2045(15)00482-9","volume":"17","author":"AJ Hayes","year":"2016","unstructured":"Hayes AJ, Maynard L, Coombes G, Newton-Bishop J, Timmons M, Cook M, et al. Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial. Lancet Oncol. 2016;17:184\u201392.","journal-title":"Lancet Oncol"},{"key":"1361_CR49","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1038\/jid.2008.41","volume":"128","author":"JP North","year":"2008","unstructured":"North JP, Kageshita T, Pinkel D, LeBoit PE, Bastian BC. Distribution and significance of occult intraepidermal tumor cells surrounding primary melanoma. J Invest Dermatol. 2008;128:2024\u201330.","journal-title":"J Invest Dermatol"},{"key":"1361_CR50","unstructured":"National Comprehensive Cancer N. NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous (Version 1.2025). 2025."},{"key":"1361_CR51","doi-asserted-by":"publisher","first-page":"115153","DOI":"10.1016\/j.ejca.2024.115153","volume":"215","author":"C Garbe","year":"2025","unstructured":"Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024. Eur J Cancer. 2025;215:115153.","journal-title":"Eur J Cancer"},{"key":"1361_CR52","doi-asserted-by":"publisher","first-page":"115152","DOI":"10.1016\/j.ejca.2024.115152","volume":"215","author":"C Garbe","year":"2025","unstructured":"Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024. Eur J Cancer. 2025;215:115152.","journal-title":"Eur J Cancer"},{"key":"1361_CR53","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","volume":"36","author":"T Amaral","year":"2025","unstructured":"Amaral T, Ottaviano M, Arance A, Blank C, Chiarion-Sileni V, Donia M, et al. Cutaneous melanoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36:10\u201330.","journal-title":"Ann Oncol"},{"key":"1361_CR54","doi-asserted-by":"crossref","unstructured":"Ito T, Kaku-Ito Y, Wada-Ohno M, Furue M. Narrow-Margin excision for invasive acral melanoma: is it acceptable? J Clin Med. 2020;9.","DOI":"10.3390\/jcm9072266"},{"key":"1361_CR55","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1007\/s00403-023-02609-2","volume":"315","author":"W Sun","year":"2023","unstructured":"Sun W, Xu Y, Qu X, Jin Y, Wang C, Yan W, et al. Surgical resection margin for T3-T4 primary acral melanoma: a multicenter retrospective cohort study. Arch Dermatol Res. 2023;315:2305\u201312.","journal-title":"Arch Dermatol Res"},{"key":"1361_CR56","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1001\/jamadermatol.2023.0620","volume":"159","author":"A Maurichi","year":"2023","unstructured":"Maurichi A, Barretta F, Patuzzo R, Sala L, Miceli R, Gallino G, et al. Association of excision margin size with local recurrence and survival in patients with T1a melanoma at critical structures. JAMA Dermatol. 2023;159:587\u201395.","journal-title":"JAMA Dermatol"},{"key":"1361_CR57","first-page":"38","volume":"159","author":"LS Lino-Silva","year":"2023","unstructured":"Lino-Silva LS, Hern\u00e1ndez-Romero R, Garc\u00eda-Herrera JS, Zepeda-Najar C, Salcedo-Hern\u00e1ndez RA, Le\u00f3n-Takahashi AM, et al. Recurrence rate and survival implications of surgical margins in patients with acral melanoma. Is a wide margin necessary? Gac Med Mex. 2023;159:38\u201343.","journal-title":"Gac Med Mex"},{"key":"1361_CR58","doi-asserted-by":"publisher","first-page":"110264","DOI":"10.1016\/j.ejso.2025.110264","volume":"51","author":"S Koizumi","year":"2025","unstructured":"Koizumi S, Yamazaki N, Ichigozaki Y, Kitagawa H, Kiniwa Y, Sato S, et al. Comparing 2\u00a0cm vs. 1\u00a0cm surgical margins in acral melanoma of the sole with Breslow thickness greater than 2\u00a0mm: A multicenter retrospective study of 336 Japanese patients. Eur J Surg Oncol. 2025;51:110264.","journal-title":"Eur J Surg Oncol"},{"key":"1361_CR59","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/1097-0142(196409)17:9<1159::AID-CNCR2820170910>3.0.CO;2-8","volume":"17","author":"G Olsen","year":"1964","unstructured":"Olsen G. Removal of fascia\u2013cause, of more frequent metastases of malignant melanomas of the skin to regional lymph. Nodes? Cancer. 1964;17:1159\u201364.","journal-title":"Cancer"},{"key":"1361_CR60","first-page":"615","volume":"92","author":"DE Kenady","year":"1982","unstructured":"Kenady DE, Brown BW, McBride CM. Excision of underlying fascia with a primary malignant melanoma: effect on recurrence and survival rates. Surgery. 1982;92:615\u20138.","journal-title":"Surgery"},{"key":"1361_CR61","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.surg.2012.09.009","volume":"153","author":"TE Grotz","year":"2013","unstructured":"Grotz TE, Glorioso JM, Pockaj BA, Harmsen WS, Jakub JW. Preservation of the deep muscular fascia and locoregional control in melanoma. Surgery. 2013;153:535\u201341.","journal-title":"Surgery"},{"key":"1361_CR62","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1111\/bjd.13478","volume":"171","author":"RE Hunger","year":"2014","unstructured":"Hunger RE, Seyed Jafari SM, Angermeier S, Shafighi M. Excision of fascia in melanoma thicker than 2 mm: no evidence for improved clinical outcome. Br J Dermatol. 2014;171:1391\u20136.","journal-title":"Br J Dermatol"},{"key":"1361_CR63","doi-asserted-by":"publisher","first-page":"109573","DOI":"10.1016\/j.surg.2025.109573","volume":"186","author":"S Koizumi","year":"2025","unstructured":"Koizumi S, Yamazaki N, Ichigozaki Y, Kitagawa H, Kiniwa Y, Sato S, et al. Prognosis of a deep excision margin within or beyond subcutaneous fat for invasive acral melanoma of the sole: A multi-institutional retrospective study. Surgery. 2025;186:109573.","journal-title":"Surgery"},{"key":"1361_CR64","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1467-2494.2007.00372.x","volume":"29","author":"DAR De Berker","year":"2007","unstructured":"De Berker DAR, Andr\u00e9 J, Baran R. Nail biology and nail science. Int J Cosmet Sci. 2007;29:241\u201375.","journal-title":"Int J Cosmet Sci"},{"key":"1361_CR65","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/1346-8138.12622","volume":"41","author":"Y Nakamura","year":"2014","unstructured":"Nakamura Y, Fujisawa Y, Teramoto Y, Sato S, Yamada K, Sekine K, et al. Tumor-to-bone distance of invasive subungual melanoma: an analysis of 30 cases. J Dermatol. 2014;41:872\u20137.","journal-title":"J Dermatol"},{"key":"1361_CR66","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jaad.2022.12.039","volume":"88","author":"BH Oh","year":"2023","unstructured":"Oh BH, Lee S, Park JW, Lee JY, Roh MR, Nam KA, et al. Risk of recurrence of nail unit melanoma after functional surgery versus amputation. J Am Acad Dermatol. 2023;88:1017\u201323.","journal-title":"J Am Acad Dermatol"},{"key":"1361_CR67","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1186\/s12885-019-6248-2","volume":"19","author":"K Tanaka","year":"2019","unstructured":"Tanaka K, Nakamura Y, Mizutani T, Shibata T, Tsutsumida A, Fukuda H, et al. Confirmatory trial of non-amputative digit preservation surgery for Subungual melanoma: Japan clinical oncology group study (JCOG1602, J-NAIL study protocol). BMC Cancer. 2019;19:1002.","journal-title":"BMC Cancer"},{"key":"1361_CR68","doi-asserted-by":"crossref","unstructured":"Lewis DJ. Practical interventions to optimize patient adherence in dermatologic surgery and Mohs micrographic surgery: A review. Dermatol Surg. 2025.","DOI":"10.1097\/DSS.0000000000004736"},{"key":"1361_CR69","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.det.2025.03.003","volume":"43","author":"J Burshtein","year":"2025","unstructured":"Burshtein J, Marson J, Shah M, Zakria D, DeBusk L, Rosenberg A, et al. Mohs micrographic surgery for melanoma. Dermatol Clin. 2025;43:473\u201382.","journal-title":"Dermatol Clin"},{"key":"1361_CR70","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jaad.2022.12.018","volume":"88","author":"T Huerta","year":"2023","unstructured":"Huerta T, Swetter SM, Nehal KS, Coit DG, Bichakjian CK, Durham AB. Current evidence does not support Mohs micrographic surgery or staged excision as equivalent to wide excision for primary cutaneous melanoma. J Am Acad Dermatol. 2023;88:959\u201360.","journal-title":"J Am Acad Dermatol"},{"key":"1361_CR71","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/jdv.20138","volume":"39","author":"GJ Williams","year":"2025","unstructured":"Williams GJ, Quinn T, Lo S, Guitera P, Scolyer RA, Thompson JF, et al. Mohs micrographic surgery for the treatment of invasive melanoma: a systematic review with meta-analyses. J Eur Acad Dermatol Venereol. 2025;39:416\u201325.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1361_CR72","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1097\/DSS.0000000000002827","volume":"47","author":"J Seo","year":"2021","unstructured":"Seo J, Oh Y, Kim SK, Roh MR, Chung KY. Slow Mohs micrographic surgery for acral melanoma treatment in Korean patients. Dermatol Surg. 2021;47:e42\u20136.","journal-title":"Dermatol Surg"},{"key":"1361_CR73","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.jaad.2024.11.078","volume":"92","author":"KL Valdes Morales","year":"2025","unstructured":"Valdes Morales KL, Frankel D, Trifoi MD, Lin SK, Deitermann AM, Lubeck M, et al. Nail unit melanoma treated with Mohs micrographic surgery: technique, local recurrence rate, and surgical outcomes. J Am Acad Dermatol. 2025;92:1072\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"1361_CR74","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jaad.2022.09.040","volume":"88","author":"AB Shannon","year":"2023","unstructured":"Shannon AB, Sharon CE, Straker RJ 3rd, Carr MJ, Sinnamon AJ, Bogatch K, et al. Sentinel lymph node biopsy in patients with T1a cutaneous malignant melanoma: A multicenter cohort study. J Am Acad Dermatol. 2023;88:52\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"1361_CR75","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1245\/s10434-016-5137-z","volume":"23","author":"E Cordeiro","year":"2016","unstructured":"Cordeiro E, Gervais M-K, Shah PS, Look Hong NJ, Wright FC. Sentinel lymph node biopsy in thin cutaneous melanoma: a systematic review and meta-analysis. Ann Surg Oncol. 2016;23:4178\u201388.","journal-title":"Ann Surg Oncol"},{"key":"1361_CR76","doi-asserted-by":"crossref","unstructured":"Stassen RC, Schurink AW, van der Veldt AAM, Hollestein LM, Verhoef C, Gr\u00fcnhagen DJ. Critical evaluation of Sentinel lymph node biopsy in pT1b and pT2a melanoma patients: A nationwide population-based study. Eur J Cancer. 2025;220.","DOI":"10.1016\/j.ejca.2025.115365"},{"key":"1361_CR77","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1245\/s10434-014-3641-6","volume":"21","author":"C Mitteldorf","year":"2014","unstructured":"Mitteldorf C, Bertsch HP, Jung K, Thoms K-M, Sch\u00f6n MP, Tronnier M, et al. Sentinel node biopsy improves prognostic stratification in patients with thin (pT1) melanomas and an additional risk factor. Ann Surg Oncol. 2014;21:2252\u20138.","journal-title":"Ann Surg Oncol"},{"key":"1361_CR78","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.1245\/s10434-025-16971-0","volume":"32","author":"AS Van Doren","year":"2025","unstructured":"Van Doren AS, Shah H, Ata A, Davis L. An evaluation of sentinel lymph node biopsy guideline adherence in melanoma. Ann Surg Oncol. 2025;32:5283\u201391.","journal-title":"Ann Surg Oncol"},{"key":"1361_CR79","doi-asserted-by":"publisher","first-page":"9655","DOI":"10.2147\/CMAR.S227837","volume":"11","author":"JW Chang","year":"2019","unstructured":"Chang JW, Huang YL, Chang YY, Lo YF, Ho TY, Huang YT, et al. Sentinel lymph node biopsy was associated with favorable survival outcomes for patients with clinically node-Negative Asian melanoma. Cancer Manag Res. 2019;11:9655\u201364.","journal-title":"Cancer Manag Res"},{"key":"1361_CR80","doi-asserted-by":"crossref","unstructured":"Farooq MS, Shafique N, Vargas GM, Varey AHR, Lo SN, Chu EY et al. Utility of Sentinel lymph node biopsy for acral lentiginous melanoma in the contemporary era: A National cohort analysis. J Am Acad Dermatol. 2025.","DOI":"10.1016\/j.jid.2025.06.232"},{"key":"1361_CR81","doi-asserted-by":"crossref","unstructured":"Bellomo D, Arias-Mejias SM, Ramana C, Heim JB, Quattrocchi E, Sominidi-Damodaran S et al. Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma. JCO Precision Oncology. 2020:319\u2009\u2013\u200934.","DOI":"10.1200\/PO.19.00206"},{"key":"1361_CR82","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejca.2022.12.021","volume":"182","author":"T Amaral","year":"2023","unstructured":"Amaral T, Sinnberg T, Chatziioannou E, Niessner H, Leiter U, Keim U, et al. Identification of stage I\/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP). Eur J Cancer. 2023;182:155\u201362.","journal-title":"Eur J Cancer"},{"key":"1361_CR83","doi-asserted-by":"publisher","unstructured":"Wong T, Ch\u2019ng S, Ferguson P, Martin L, Menzies AM, Silva IPd, et al. Predictive performance of the clinicopathologic gene expression profile (CP-GEP) in identifying cutaneous melanoma patients for whom sentinel lymph node biopsy is unnecessary: a systematic review and meta-analysis. Crit Rev Oncol\/Hematol. 2025. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104816.","DOI":"10.1016\/j.critrevonc.2025.104816"},{"key":"1361_CR84","doi-asserted-by":"publisher","first-page":"115372","DOI":"10.1016\/j.ejca.2025.115372","volume":"220","author":"T Amaral","year":"2025","unstructured":"Amaral T, Chatziioannou E, Nuebling A, Nanz L, Sinnberg T, Niessner H, et al. Risk stratification using the Merlin assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I\/II melanoma who did not undergo Sentinel lymph node biopsy. Eur J Cancer. 2025;220:115372.","journal-title":"Eur J Cancer"},{"key":"1361_CR85","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1007\/s10147-021-02029-0","volume":"26","author":"D Ogata","year":"2021","unstructured":"Ogata D, Tanese K, Nakamura Y, Otsuka M, Namikawa K, Funakoshi T, et al. Impact of the changes in the completion lymph node dissection criteria and approval of adjuvant therapies on the real-world outcomes of Japanese stage III melanoma patients. Int J Clin Oncol. 2021;26:2338\u201346.","journal-title":"Int J Clin Oncol"},{"key":"1361_CR86","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1245\/s10434-019-07830-w","volume":"27","author":"DM Bello","year":"2020","unstructured":"Bello DM, Faries MB. The landmark series: MSLT-1, MSLT-2 and DeCOG (management of lymph nodes). Ann Surg Oncol. 2020;27:15\u201321.","journal-title":"Ann Surg Oncol"},{"key":"1361_CR87","unstructured":"Broman KK, Hughes TM, Bredbeck BC, Sun J, Kirichenko D, Carr MJ et al. International Center-Level variation in utilization of completion lymph node dissection and adjuvant systemic therapy for Sentinel lymph node-Positive melanoma at major referral centers. Ann Surg. 2023;277."},{"key":"1361_CR88","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamadermatol.2021.4812","volume":"158","author":"S Cheraghlou","year":"2022","unstructured":"Cheraghlou S, Ugwu N, Girardi M. Sentinel lymph node biopsy positivity in patients with acral lentiginous and other subtypes of cutaneous melanoma. JAMA Dermatol. 2022;158:51\u20138.","journal-title":"JAMA Dermatol"},{"key":"1361_CR89","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1007\/s10147-025-02747-9","volume":"30","author":"Y Fujisawa","year":"2025","unstructured":"Fujisawa Y, Yoshikawa S, Takenouchi T, Mori S, Asai J, Uhara H, et al. Melanoma skin cancer statistics derived from 7442 Japanese patients: Japanese melanoma study. Int J Clin Oncol. 2025;30:844\u201355.","journal-title":"Int J Clin Oncol"},{"key":"1361_CR90","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/pcmr.13113","volume":"36","author":"CC Hsu","year":"2023","unstructured":"Hsu CC, Liao YH, Sheen YS. Survival benefit of sentinel lymph node biopsy in Asian melanoma patients. Pigment Cell Melanoma Res. 2023;36:522\u201330.","journal-title":"Pigment Cell Melanoma Res"},{"key":"1361_CR91","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1007\/s10238-023-01107-z","volume":"23","author":"J Zhong","year":"2023","unstructured":"Zhong J, Zou Z, Hu T, Sun W, Wang C, Yan W, et al. Survival impact of immediate complete lymph node dissection for Chinese acral and cutaneous melanoma with micrometastasis in Sentinel nodes: a retrospective study. Clin Exp Med. 2023;23:4003\u201310.","journal-title":"Clin Exp Med"},{"key":"1361_CR92","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y, Wright GP Jr., Yost KJ, Hyngstrom JR, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388:813\u201323.","journal-title":"N Engl J Med"},{"key":"1361_CR93","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med. 2024;391:1696\u2013708.","journal-title":"N Engl J Med"},{"key":"1361_CR94","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","volume":"20","author":"EA Rozeman","year":"2019","unstructured":"Rozeman EA, Menzies AM, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20:948\u201360.","journal-title":"Lancet Oncol"},{"key":"1361_CR95","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","volume":"28","author":"ILM Reijers","year":"2022","unstructured":"Reijers ILM, Menzies AM, van Akkooi ACJ, Versluis JM, van den Heuvel NMJ, Saw RPM, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28:1178\u201388.","journal-title":"Nat Med"},{"key":"1361_CR96","doi-asserted-by":"publisher","first-page":"115141","DOI":"10.1016\/j.ejca.2024.115141","volume":"214","author":"ILM Reijers","year":"2025","unstructured":"Reijers ILM, Menzies AM, Lopez-Yurda M, Versluis JM, Rozeman EA, Saw RPM, et al. Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: comparison of 3-year data from PRADO and OpACIN-neo. Eur J Cancer. 2025;214:115141.","journal-title":"Eur J Cancer"},{"key":"1361_CR97","doi-asserted-by":"publisher","first-page":"9512","DOI":"10.1200\/JCO.2025.43.16_suppl.9512","volume":"43","author":"L Mao","year":"2025","unstructured":"Mao L, Li C, Dai J, Wei X, Gu J, Du Y, et al. Neoadjuvant camrelizumab plus apatinib and Temozolomide for resectable stage II\/III acral melanoma: the CAP 03-NEO trial. J Clin Oncol. 2025;43:9512.","journal-title":"J Clin Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01361-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01361-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01361-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T14:02:50Z","timestamp":1763647370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01361-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":97,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1361"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01361-1","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Yasuhiro Nakamura has received research funding and has served as a consultant and\/or received honoraria from Alexion Pharma, Bristol-Myers Squibb, Dai-ichi Sankyo, HUYA Bioscience International, Kyowa Kirin, LEO Pharma, Maruho, MSD, Novartis Ono Pharma, Pierre Fabre, Sanofi, Sun Pharma, and Tanabe-Mitsubishi Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}